Appendix 4E and 2026 Annual Report
Filed with ASX · · 94 pages · English
Story so far
Earlier from Dimerix
- Dimerix Receives US$10M Upfront Payment from Everest
- Dimerix Assumes Sponsorship of US IND for New Asset DMX-652
- Dimerix Presents at Bioshares Summit 2026
- US Patent Granted for Dimerix New Asset DMX-652
- Dimerix expands pipeline with acquisition of Phase 2 ready asset for acute kidney injury
Later from Dimerix
- Dimerix Secures A$34 Million Non-Dilutive Funding Facility
- Dimerix secures a$34 million non-dilutive facility to fund key clinical milestones
- S&P DJI Announces September 2026 Quarterly Rebalance
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix